ActiGraph, a leading provider of objective physical activity and sleep/wake monitoring solutions for the global research community, announced today the release of an Application Programming Interface (API) to its popular ActiLife analysis software. The newest addition to ActiGraph’s growing technology suite, the ActiLife API was designed to run within closed systems, ensuring that protocol and regulation compliance requirements are not compromised during data collection.
ActiGraph’s new API allows programmatic control of the ActiLife software over a standard socket, allowing users to develop their own custom applications (Java, C#, C++, etc.) which can automate activity monitor deployments and downloads. An active Internet connection is not required and the ActiLife user interface control can be completely blocked from view, allowing full integration and automation of custom client applications. The ActiLife API currently supports all ActiGraph devices, including the company’s newest wireless wGT3X+ and wActiSleep+ monitors.
“The ActiLife API was primarily developed to support the implementation of ActiGraph’s objective monitoring system within drug trials and clinical research studies,” said Jeremy Wyatt, ActiGraph’s Vice President of Software Engineering. “The tremendous value of objective measures within these markets is finally becoming fully understood, and we are focused on developing tools, like the ActiLife API, that deliver data seamlessly in these complex environments.”
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Funding Cuts Threaten Diversity in Clinical Research
June 27th 2025In this video interview, Kyle McAllister, co-founder, CEO, Trially, discusses how recent federal funding cuts are likely to undermine research focused on underrepresented populations, and why long-term investment in community-based studies is essential to closing persistent health equity gaps.